Trial Profile

Phase 2b clinical trial assessing Trichomylin softgel capsules

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 May 2025 According to ZYUS Life Sciences media release, insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2.
30 Jul 2024 According to ZYUS Life Sciences media release, company has received a No Objection Letter from Health Canada for a proof-of-concept trial respecting of Trichomylin softgel capsules.
04 Jun 2024 According to ZYUS Life Sciences media release, the company has received a Cannabis Drug License issued pursuant to the Cannabis Act (Canada) and Cannabis Regulations which pertains specifically to its processing facility located in Saskatoon, Saskatchewan. This license provides a robust framework for the manufacture of Trichomylin softgel capsules for this Phase 2 Clinical Trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com